Echocardiographic evaluation of anti-Tumor Necrosis Factor-α therapy with infliximab in patients without cardiac pathologies;Effetti del trattamento anti-Tumor Necrosis Factor-α con infliximab in pazienti non cardiopatici: Valutazione ecocardiografica

Recenti Progressi in Medicina

Volumn 101, Issue 7-8, 2010, Pages 289-292

  Bragagni, Gianpaolo ^a   Lari, Federico ^a   Magenta, Gaetano ^a   Brogna, Raffaele ^b   Zoli, Giorgio ^b  

^a Azienda USL di Bologna   (Italy)

^b Ospedale SS Annunziata di Cento   (Italy)

Author keywords

Heart failure; Infliximab; Tumor Necrosis Factor

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART MUSCLE; HEART PROTECTION; HUMAN; MALE; SYSTOLIC BLOOD PRESSURE; ANIMAL; BEHCET SYNDROME; BLOOD; COMPARATIVE STUDY; CROHN DISEASE; DIASTOLE; DISEASE MODEL; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; EVALUATION STUDY; KNOCKOUT MOUSE; MIDDLE AGED; MORTALITY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CROHN DISEASE; DIASTOLE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GASTROINTESTINAL AGENTS; HEART FAILURE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; SYSTOLE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957303891     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: 10.1701/508.6080     Document Type: Article

References (25)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor α in severe chronic heart failure. N Engl J Med 1990; 223: 236-41.
2. Torre-Amione G, Vooletich MT, Farmer JA. Role of tumor necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs 2000; 59: 745-51. (Pubitemid 30232317)
3. Kubota T, Mc Tiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-35.
4. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodelling in progression of heart failure: a current perspective. Cardiovasc Res 2002; 53: 822-30.
5. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-12. (Pubitemid 23333536)
6. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48: 68-75. (Pubitemid 36091536)
7. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-bind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe chronic heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
8. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept World Evaluation (RENEWAL). Circulation 2004; 109: 1594-602. (Pubitemid 38451714)
9. Anker SD, Coats AJ. How to recover from renaissance? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86: 123-30.
10. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, et al. Does tumor necrosis factor alpha promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58: 667-77.
11. Kwon HJ, Cotè TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
12. Shiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography J Am Soc Echocardiogr 1989; 2: 358-67.
13. Spirito P, Maron BJ. Doppler echocardiography for assessing left ventricular diastolic function. Ann Intern Med 1988; 15: 122-6.
14. Bragagni G, Brogna R, Franceschetti P, Zoli G. Cardiac involvement in Crohn's disease: echocardiographic study. J Gastroenterol Hepatol 2007; 22: 18-22. (Pubitemid 44953410)
15. Doria A, Puttini PC, Shoenfeld Y. Heart, rheumatism and autoimmunity. Autoimmun Rev 2004; 3: 337-54.
16. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in inconscious dogs. J Clin Invest 1992; 90: 389-98.
17. Peters MJ, Welsh P, McInnes IB, Wolbink GJ, Dijkmans BA, Sattar N, et al. TNF-alpha blockade therapy reduces circulating NT-proBNP levels in RA patients with active disease: results from prospective cohort study. Ann Rheum Dis 2010; [Epub ahead of print].
18. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994; 34: 17-40.
19. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signalling in TNF-alpha and ischemic preconditioning mediated cardioprotetion. J Mol Cell Cardiol 2002; 34: 509-18.
20. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, Opie LH. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer anf activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and Extracellular Signal-Regulated Kinase). Circulation 2005; 112: 3911-8. (Pubitemid 43739489)
21. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, Feldman AM. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodelling in transgenic mice with tumor necrosis factor-α-induced cardiomyopathy. Circulation 2004; 109: 1892-7.
22. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, et al. Divergent tumor necrosis factor receptor-related remodelling responses in heart failure: role of nuclear factor-kappa B and inflammatory activation. Circulation 2009; 119: 1386-97.
23. Wang M, Tsai BM, Crisostomo PR, Meldrum DR. Tumor necrosis factor receptor 1 signalling resistance in the female myocardium during ischemia. Circulation 2006; 114 (suppl I): I-282-I-289. (Pubitemid 44297164)
24. Kawamura N, Kubota T, Kawano S, Monden Y, Feldman AM, Tsutsui H, et al. Blockade of NF-κB improves cardiac function and survival without affecting inflammation in TNF-α-induced cardiomyopathy. Cardiovasc Res 2005; 66: 520-9.
25. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor Necrosis Factor-α confers resistance to hypoxic injury in the adult mammalian cardiac myocite. Circulation 1998; 97: 1392-400.